-
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
05 Aug 2025 11:30 GMT
… More information about the trial is available at … notably difficult to treat, with over 50% … prostate cancer at all stages. FX-111 is undergoing Investigational New Drug … for the treatment of metastatic castration-resistant prostate cancer (mCRPC). …
-
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
04 Aug 2025 17:00 GMT
… neuroendocrine prostate cancer treatment options @ Neuroendocrine Prostate Cancer Treatment Guidelines Neuroendocrine Prostate Cancer Emerging Drugs and … BMS, RayzeBio, Radiomedix, Orano Med, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, …
-
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
04 Aug 2025 13:51 GMT
… better manage and treat their patients in … treatment selection in metastatic castration-sensitive prostate cancer (mCSPC)?
Treatment … hematologic profile, and drug-drug interactions, which require … the [phase 3] PSMAddition Trial [NCT04720157] was positive, …
-
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
04 Aug 2025 12:00 GMT
… INKmune™ INKmune™ is a pharmaceutical-grade, replication-incompetent human … friendly drug treatment that does not require pre-medication, conditioning … can be used to treat many types of NK … in a trial in metastatic castration-resistance prostate cancer. The …
-
Phase 1/2 trial of INKmune therapy for mCRPC meets primary end point
05 Aug 2025 01:07 GMT
… company, “INKmune is a pharmaceutical-grade, replication-incompetent human … or completely disappearing during treatment, so we believe this … robust measurement of the drug's effects … Inc. expands INKmune trial in prostate cancer to veterans. News release …
-
Medicus Pharma and HelixNano agree outline deal to develop...
04 Aug 2025 21:35 GMT
Medicus Pharma (NASDAQ:MDCX) has agreed a … used in a human clinical trial.
Medicus, which also operates through … -based business developing a drug for advanced prostate cancer, though that deal still …
-
Pharma Pulse 8/4/25: Adapting to a Changing Research Funding Landscape; Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
04 Aug 2025 10:20 GMT
… drug approvals and enabling more efficient clinical trial … United States to treat a patient with … the law.
Advancing Prostate Cancer Treatment with Shared Decision-Making … . emphasized that effective prostate cancer care—particularly for localized …
-
Smart Hybrids Fight Breast and Prostate Cancer
02 Aug 2025 05:02 GMT
… and prostate cancer are aggressive and hard to treat due to … comparably to standard drugs like cisplatin and 5 … drug doxorubicin.
These hybrids could lead to new anticancer drugs … that are more selective and effective, especially for hard-to-treat …
-
Biopsy grade alone may underestimate risk in GG1 prostate cancer
02 Aug 2025 02:48 GMT
Recent data published in JAMA Oncology show that 1 in 6 men with grade group 1 (GG1) prostate cancer ultimately had intermediate- to high-risk disease when other clinical features were taken into account.1
According to the authors, these data suggest that …
-
Advancing Prostate Cancer Treatment With Shared Decision-Making
01 Aug 2025 15:02 GMT
In this episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss the treatment of localized prostate cancer, highlighting the importance of shared decision-making and multidisciplinary collaboration.
Episode Highlights
0:53 | …